D. Bunjes

A. Ganser, N. Kröger, M. Labopin, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients

M. Labopin, J. Finke, M. Mohty, 2012, Journal of internal medicine.

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

M. Labopin, J. Finke, M. Mohty, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients

D. Bunjes, J. Greiner, M. Götz, 2019, Journal of clinical medicine.

Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders

H. Döhner, M. Schmitt, D. Bunjes, 2018, International journal of cancer.

Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma

L. Kanz, H. Dittmann, D. Bunjes, 2012, Bone Marrow Transplantation.

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.

C. Meisner, L. Kanz, H. Dittmann, 2007, Blood.

Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.

H. Döhner, Baoan Chen, K. Giannopoulos, 2007, International journal of oncology.

Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)‐positive acute myeloblastic leukemia by real‐time RT‐PCR

A. Ganser, M. Wattjes, O. Heidenreich, 2001, Genes, chromosomes & cancer.

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.

H. Döhner, Baoan Chen, M. Rojewski, 2008, Experimental hematology.

FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

F. Kuchenbauer, D. Bunjes, P. Ungprasert, 2019, Journal of clinical medicine.

Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome

H. Heimpel, J. Duyster, L. Bergmann, 2000, Bone Marrow Transplantation.

Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia

H. Heimpel, W. Kern, R. Arnold, 2005, Annals of Hematology.

The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice

S. Meri, S. Jodele, D. Bunjes, 2022, Advances in Therapy.

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

M. Dyer, D. Catovsky, G. Pangalis, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.

G. Glatting, S. Reske, K. Hohl, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML.

D. Bunjes, Donald Bunjes, 2001, Cytotherapy.

Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells

H. Döhner, Baoan Chen, M. Rojewski, 2009, British journal of haematology.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

M. Neuenhahn, D. Busch, H. Einsele, 2017, Leukemia.

High dose RHAMM-R 3 peptide vaccination for patients with acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) and multiple myeloma ( MM )

H. Döhner, K. Giannopoulos, M. Rojewski, 2010 .

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

H. Döhner, K. Giannopoulos, M. Rojewski, 2010, Haematologica.

Bacteremia in an Immunocompromised Patient Caused by a Commensal Neisseria meningitidis Strain Harboring the Capsule Null Locus (cnl)

M. Frosch, H. Claus, U. Vogel, 2004, Journal of Clinical Microbiology.

Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant.

M. Clausen, B. Hertenstein, D. Bunjes, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

for chronic lymphocytic leukemia containing conditioning regimen and autologous stem cell transplantation Autologous graft versus host disease-like syndrome after an alemtuzumab

R. Schlenk, H. Döhner, M. Hallek, 2013 .

transplantation for chronic lymphocytic leukemia cell alemtuzumab-containing conditioning regimen and autologous stem like syndrome after an - Autologous graft-versus-host disease

R. Schlenk, H. Döhner, M. Hallek, 2012 .

Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.

R. Schlenk, H. Döhner, M. Hallek, 2006, Blood.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

H. Putter, N. Kröger, J. Finke, 2017, Bone Marrow Transplantation.

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

N. Schmitz, H. Döhner, P. Paschka, 2013, Blood.

Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia.

E. Holler, G. Kobbe, S. Schönland, 2022, Transplantation and cellular therapy.

The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice

S. Meri, S. Jodele, D. Bunjes, 2022, Advances in Therapy.

Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied

D. Huhn, A. Ganser, J. Duyster, 1998, Annals of Hematology.

marrow transplantation graft-versus-host disease after allogeneic HLA-identical sibling bone secreting T-helper cell precursors in patients with and without acute Quantitative assessment of posttransplant host-specific interleukin-2-

H. Heimpel, R. Arnold, M. Theobald, 2011 .

Pretransplant detection of human minor histocompatibility antigen-specific naive and memory interleukin-2-secreting T cells within class I major histocompatibility complex (MHC)-restricted CD8+ and class II MHC-restricted CD4+ T-cell subsets.

M. Theobald, D. Bunjes, 1993, Blood.

Quantitative assessment of posttransplant host-specific interleukin-2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation.

H. Heimpel, R. Arnold, M. Theobald, 1993, Blood.

Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings.

H. Heimpel, R. Arnold, M. Theobald, 1992, The New England journal of medicine.

Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2

M. Röllinghoff, D. Bunjes, C. Hardt, 1981, European journal of immunology.

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

N. Schmitz, H. Döhner, M. Hallek, 2008, Leukemia.

EVIDENCE FOR THE INVOLVEMENT OF HOST‐DERIVED OKT8‐POSITIVE T CELLS IN THE REJECTION OF T‐DEPLETED, HLA‐IDENTICAL BONE MARROW GRAFTS

H. Heimpel, F. Porzsolt, D. Bunjes, 1987, Transplantation.

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.

R. Schlenk, D. Speiser, S. Gnjatic, 2008, Blood.

Psoralen plus ultraviolet‐A‐bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease

M. Kerscher, U. Leiter, D. Bunjes, 2002, Photodermatology, photoimmunology & photomedicine.

Optimal preloading in radioimmunotherapy with anti-cD45 antibody.

G. Glatting, S. Reske, M. Luster, 2011, Medical physics.

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.

K. Schwarz, H. Einsele, M. Pfreundschuh, 2013, Blood.

Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT

A. Ganser, N. Kröger, M. Labopin, 2020, Leukemia & lymphoma.

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia

C. Craddock, A. Zander, M. Labopin, 2011, Leukemia.

Real-Time RT-PCR for the Detection and Quantification of AML1/MTG8 Fusion Transcripts in Patients with t(8;21) Positive AML

A. Ganser, M. Wattjes, L. Bergmann, 2001 .

Real‐time RT‐PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)‐positive AML patients

A. Ganser, M. Wattjes, L. Bergmann, 1999, British journal of haematology.

Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation

H. Einsele, A. Buck, A. Beer, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

B. Dörken, H. Einsele, A. Ganser, 2019, Leukemia.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

M. Cazzola, H. Deeg, P. Greenberg, 2011 .

German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells

N. Schmitz, H. Einsele, W. Friedrich, 1997, Bone Marrow Transplantation.

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

W. Hiddemann, G. Ledderose, M. Hallek, 2006, Blood.

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

L. Bullinger, H. Döhner, H. Einsele, 2017, Leukemia.

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome

L. Bullinger, K. Döhner, R. Schlenk, 2018, Bone Marrow Transplantation.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

C. Bloomfield, R. Larson, K. Mrózek, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation

H. Döhner, D. Bunjes, M. Bommer, 2010, Haematologica.

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

G. Hale, H. Waldmann, W. Fibbe, 2000, Bone Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV

Martin C. Müller, J. Hasford, A. Zander, 2008 .

Effects of nilotinib on regulatory T cells: the dose matters

Baoan Chen, M. Rojewski, M. Schmitt, 2010, Molecular Cancer.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2019, Bone Marrow Transplantation.

Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.

H. Heimpel, H. Schrezenmeier, B. Hertenstein, 1995, Blood.

Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation

A. Ganser, N. Kröger, H. Sengeløv, 2013, Haematologica.

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.

R. Brand, A. Gratwohl, D. Niederwieser, 2002, Blood.

Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells

N. Schmitz, W. Siegert, H. Einsele, 2001, Annals of Hematology.

In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.

H. Heimpel, T. Mertens, R. Arnold, 1995, Bone marrow transplantation.

Neurological outcome after a severe herpes simplex encephalitis treated with acyclovir and β-interferon time course of intracranial pressure

W. Koenig, V. Hombach, D. Bunjes, 1990, Klinische Wochenschrift.

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

A. Ganser, E. Weissinger, E. Holler, 2020, Leukemia.

Association Between The Hematopoietic Cell Transplantation-Specific Comorbidity Index (CIn) And Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1)

N. Kröger, M. Labopin, D. Blaise, 2010 .

Antiviral treatment of cytomegalovirus infection and resistant strains

A. Schreiber, D. Michel, T. Mertens, 2009 .

Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation

H. Einsele, A. Elmaagacli, D. Bunjes, 2003, Transplantation.

results of the German CLL Study Group CLL3X trial poor-risk chronic lymphocytic leukemia: long-term clinical and MRD Allogeneic stem cell transplantation provides durable disease control in

N. Schmitz, M. Hallek, S. Stilgenbauer, 2011 .

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

N. Schmitz, H. Döhner, M. Hallek, 2010, Blood.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia : long-term clinical and MRD results of the German CLL Study Group CLL 3 X trial

N. Schmitz, H. Döhner, M. Hallek, 2010 .

Effect of Cyclosporine on the Frequency of LAK Precursor Cells In Vivo and In Vitro

H. Heimpel, B. Hertenstein, M. Theobald, 1992 .

Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT

L. Kanz, M. Labopin, J. Finke, 2017, Bone Marrow Transplantation.

Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation [see comments]

L. Bianchi, B. Hertenstein, N. Frickhofen, 1994 .

Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation.

L. Bianchi, B. Hertenstein, N. Frickhofen, 1994, Blood.

Severe Chlamydia pneumoniae infection in patients with neutropenia: case reports and literature review.

M. Heinemann, W. Kern, A. Essig, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.

R. Schlenk, H. Döhner, G. Glatting, 2006, Haematologica.

Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells.

H. Heimpel, M. Theobald, D. Bunjes, 1993, Bone marrow transplantation.

T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.

D. Bunjes, Donald Bunjes, 2000, Transfusion science.

T‐cell depletion versus methotrexate as GvHD‐prophylaxis in allogeneic bone marrow transplantation for leukaemia

H. Heimpel, B. Hertenstein, D. Bunjes, 1988, European journal of haematology.

Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia: No Impact of Pre-transplant Extramedullary Disease on Outcome

M. Tallman, R. Gale, T. Shea, 2015, Bone Marrow Transplantation.

remission at transplantation in adults with high-risk acute leukemia : a risk factor analysis of A survey of fully haploidentical hematopoietic stem cell transplantation

P. Bartolomeo, M. Labopin, A. Nagler, 2008 .

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

V. Diehl, G. Brittinger, D. Huhn, 2001, Annals of Hematology.

Gender, cholinesterase, platelet count and red cell count are main predictors of peripheral blood stem cell mobilization in healthy donors

A. Schulz, D. Fürst, H. Schrezenmeier, 2019, Vox sanguinis.

Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.

G. Glatting, S. Reske, M. Rentschler, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhanced Renal Toxicity of Total Body Irradiation Combined with Radioimmunotherapy

R. Wennauer, E. Röttinger, D. Bunjes, 2003, Strahlentherapie und Onkologie.

(Ph+ ALL) outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2013 .

ALL) + (Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2009 .

Emergence of CD 52-, Phosphatidylinositolglycan-Anchor-Deficient T Lymphocytes After In Vivo Application of Campath-1 H for Refractory B-Cell Non-Hodgkin Lymphoma

H. Heimpel, H. Schrezenmeier, B. Hertenstein, 2000 .

Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT

J. Johansson, N. Kröger, S. Iacobelli, 2020, British journal of haematology.

Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marr

A. Nagler, M. Mohty, N. Russell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naïve T cells

H. Döhner, M. Rojewski, D. Bunjes, 2013, Haematologica.

Fatal outcome in a patient developing Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease

K. Döhner, H. Döhner, T. Mertens, 2001, Bone Marrow Transplantation.

Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party

M. Labopin, A. Nagler, M. Mohty, 2020, Bone Marrow Transplantation.

Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes

H. Döhner, F. Kuchenbauer, D. Michel, 2020, Transplant infectious disease : an official journal of the Transplantation Society.

Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia.

H. Einsele, L. Kanz, T. Klingebiel, 2000, British journal of haematology.

Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML

D. Huhn, A. Ganser, S. Kreiter, 1998, Bone Marrow Transplantation.

Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.

H. Döhner, P. Guillaume, D. Bunjes, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

S. Montoto, N. Kröger, A. Nagler, 2018, Bone Marrow Transplantation.

Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation.

W. Friedrich, D. Bunjes, C. Duncker, 1998, Bone marrow transplantation.

Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey.

M. Labopin, A. Nagler, L. Volin, 2009 .

Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow

B. Hertenstein, D. Bunjes, R. Arnold, 1989, Infection.

Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.

H. Heimpel, B. Hertenstein, D. Bunjes, 1988, Scandinavian journal of infectious diseases.

Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation

H. Heimpel, B. Hertenstein, D. Bunjes, 1987, Klinische Wochenschrift.

Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantation

H. Heimpel, G. Hale, H. Waldmann, 1986, British journal of haematology.

CYCLOSPORINE AS AN ALTERNATIVE TO CYCLOPHOSPHAMIDE IN THE TREATMENT OF CHRONIC GRAFT‐VERSUS‐HOST DISEASE

H. Heimpel, R. Arnold, D. Bunjes, 1986, Transplantation.

Fluoroquinolones for Infection Prevention After Bone Marrow Transplantation

W. Kern, B. Hertenstein, D. Bunjes, 1994 .

First case of fatal Rhizomucor miehei endocarditis in an immunocompromised patient.

G. Walther, O. Kurzai, A. Essig, 2020, Diagnostic microbiology and infectious disease.

Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia

H. Einsele, L. Kanz, T. Klingebiel, 2000 .

Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study.

H. Döhner, L. Germeroth, C. Bechter, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CMV monitoring using blood cells and plasma: a comparison of apples with oranges?

T. Mertens, D. Bunjes, M. Wiedmann, 2007, Bone Marrow Transplantation.

Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005 .

Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse.

D. Bunjes, M. Wiesneth, B. Kubanek, 1999, Journal of hematotherapy.

Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

S. Devine, D. Weisdorf, B. Logan, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.

H. Heimpel, R. Arnold, B. Hertenstein, 1993, Transplantation.

Presence of host-specific interleukin 2-secreting T helper cell precursors correlates closely with active primary and secondary chronic graft-versus-host disease.

H. Heimpel, R. Arnold, M. Theobald, 1995, Bone marrow transplantation.

Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

J Hermans, A. Gratwohl, D. Niederwieser, 2000, Blood.

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

J. Dipersio, M. Tallman, R. Gale, 2010, Blood.

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.

Alan M. Miller, P. D. Dal Cin, J. Sierra, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.

Arnon Nagler, Myriam Labopin, Francesco Frassoni, 2008, Blood.

GRAFT REJECTION AFTER SYNGENEIC BONE MARROW TRANSPLANTATION FOR APLASTIC ANAEMIA: SIGNIFICANCE OF COCULTURE STUDIES

H. Heimpel, N. Frickhofen, D. Bunjes, 1985, British Journal of Haematology.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

H. Einsele, N. Kröger, M. Labopin, 2019, Journal of Hematology & Oncology.

High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation.

H. Heimpel, R. Arnold, F. Porzsolt, 1994, Bone Marrow Transplantation.

Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness

H. Döhner, T. Zenz, D. Bunjes, 2003, Bone Marrow Transplantation.

Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation

S. Reske, G. Steinbach, D. Bunjes, 2009, Nuklearmedizin.

Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i.

G. Glatting, A. Buck, S. Reske, 2006, Nuklearmedizin. Nuclear medicine.

Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.

H. Döhner, G. Glatting, A. Buck, 2002, Cancer biotherapy & radiopharmaceuticals.

Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation

H. Döhner, G. Glatting, A. Buck, 2001, European Journal of Nuclear Medicine.

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.

M. Horowitz, G. Hale, H. Waldmann, 1998, Blood.

ABO-incompatible bone marrow transplantation.

H. Heimpel, H. Northoff, B. Hertenstein, 1992, Beitrage zur Infusionstherapie = Contributions to infusion therapy.

Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation.

H. Heimpel, C. Bartram, B. Hertenstein, 1993, Leukemia.

CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation

L. Bergmann, D. Bunjes, C. Duncker, 2000, Bone Marrow Transplantation.

Graft failure after T cell-depleted bone marrow transplantation: clinical and immunological characteristics and response to immunosuppressive therapy.

B. Hertenstein, D. Bunjes, R. Arnold, 1990, Bone marrow transplantation.

CAMPATH-1 antibodies in stem-cell transplantation.

S. Mackinnon, G. Hale, H. Waldmann, 2001, Cytotherapy.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

J. Esteve, A. Ganser, N. Kröger, 2017, Journal of Hematology & Oncology.

Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.

H. Döhner, F. Kuchenbauer, A. Rouhi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

M. Caligiuri, C. Lengerke, B. Becher, 2018, Nature Medicine.

Frequency, specificity, and phenotype of clonally growing human alloreactive interleukin-2-secreting helper T lymphocyte precursors.

M. Theobald, D. Bunjes, W. Heit, 1990, Transplantation.

Meeting Report CAMPATH-1 antibodies in stem-cell transplantation

S. Mackinnon, G. Hale, S. Cobbold, 2001 .

Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies

G. Glatting, A. Buck, S. Reske, 2006, Nuklearmedizin.

188Re or 90Y‐labelled anti‐CD66 antibody as part of a dose‐reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study

H. Döhner, G. Glatting, A. Buck, 2005, British journal of haematology.

Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.

M. Labopin, O. Ringdén, F. Frassoni, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival of AML patients relapsing after allogeneic hematopoietic cell transplantation: a CIBMTR study

S. Devine, D. Weisdorf, B. Logan, 2015 .

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

N. Kröger, O. Kuss, D. Niederwieser, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients

R. Schlenk, H. Döhner, S. Reske, 2004, British journal of haematology.

Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients

H. Heimpel, M. Bangerter, M. Griesshammer, 1998, European journal of haematology.

Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

A. Baruchel, G. Leverger, G. Dini, 2005, Blood.

Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia

J. Sierra, M. Labopin, J. Mary, 2000, The Lancet.

In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate.

H. Heimpel, R. Arnold, B. Hertenstein, 1995, Bone marrow transplantation.

Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation.

H. Heimpel, B. Hertenstein, F. Porzsolt, 1996, Bone marrow transplantation.

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation

D. Niederwieser, C. Müller, M. Gramatzki, 2017, Haematologica.

TRANSPLANTATION Matching for the MICA-129 polymorphism is bene ﬁ cial in unrelated hematopoietic stem cell transplantation

H. Einsele, M. Pfreundschuh, D. Niederwieser, 2016 .

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis

H. Einsele, N. Kröger, H. Schrezenmeier, 2021, Frontiers in Immunology.

Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT

J. Esteve, M. Labopin, J. Finke, 2016, Bone Marrow Transplantation.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

M. Cazzola, H. Deeg, P. Greenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.

Gerhard Glatting, Sven N Reske, G. Glatting, 2007, Radiology.

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse

A. Ganser, K. Spiekermann, S. Schnittger, 2013, Haematologica.

2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma

J Kotzerke, G Glatting, H. Schirrmeister, 2001, Cancer.

Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.

R. Schlenk, H. Döhner, G. Glatting, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

A. Schulz, D. Niederwieser, M. Eyrich, 2021, Bone Marrow Transplantation.

Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation

W. Wiktor-Jedrzejczak, T. Witte, G. Gurman, 2013, Bone Marrow Transplantation.

Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis.

H. Einsele, A. Ganser, N. Kröger, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT

J. Esteve, N. Kröger, C. Craddock, 2016, Haematologica.

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches

H. Einsele, M. Boccadoro, A. Neri, 2010, Leukemia & lymphoma.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome

N. Kröger, M. Labopin, I. Yakoub-Agha, 2014, Bone Marrow Transplantation.

Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition

L. Bullinger, H. Döhner, H. Schrezenmeier, 2017, Haematologica.

Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years.

M. Beer, A. Schulz, K. Debatin, 2019, Blood advances.

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

L. Bullinger, R. Schlenk, H. Döhner, 2016, Bone Marrow Transplantation.

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses

H. Döhner, A. Ho, P. Dreger, 2017, Theranostics.

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

H. Heimpel, J. Hasford, A. Ganser, 2014, Journal of Cancer Research and Clinical Oncology.

The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.

Baoan Chen, M. Schmitt, D. Bunjes, 2007, International journal of oncology.

Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro

H. Döhner, Baoan Chen, M. Rojewski, 2007, Cancer Immunology, Immunotherapy.

Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model

Gerhard Glatting, Sven N Reske, Peter Kletting, 2009, Journal of Nuclear Medicine.

FREQUENCY ANALYSIS OF CYCLOSPORINE‐SENSITIVE CYTOTOXIC T LYMPHOCYTE PRECURSORS

W. Solbach, K. Heeg, H. Wagner, 1984, Transplantation.

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study

H. Einsele, M. Pfreundschuh, D. Niederwieser, 2017, PloS one.

Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.

H. Heimpel, B. Hertenstein, M. Theobald, 1995, Bone marrow transplantation.

Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantation

H. Kächele, D. Bunjes, N. Grulke, 2005, Bone Marrow Transplantation.

Quality of life Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantation

D. Bunjes, N. Grulke, H. Bailer, 2005 .

Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563).

T. Mertens, B. Hertenstein, D. Bunjes, 1994, Transplantation Proceedings.

Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).

A. Ganser, E. Holler, H. Greinix, 2008 .

Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes

F. Kuchenbauer, M. Sorror, D. Bunjes, 2018, Expert review of hematology.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

H. Einsele, R. Fanin, N. Kröger, 2016, Leukemia.

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

N. Kröger, I. Yakoub-Agha, S. Stilgenbauer, 2020, Bone Marrow Transplantation.

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

N. Schmitz, H. Döhner, P. Paschka, 2012 .

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

J. Esteve, N. Kröger, M. Labopin, 2021, Bone Marrow Transplantation.

Associations between coping and survival time of adult leukemia patients receiving allogeneic bone marrow transplantation: results of a prospective study.

B. Hertenstein, D. Bunjes, R. Arnold, 2001, Journal of psychosomatic research.

Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplant

T. Mertens, M. Freund, M. Schmitt, 2010, Leukemia & lymphoma.

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas

M. Engelhard, N. Kröger, J. Finke, 2016, Bone Marrow Transplantation.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party

N. Kröger, M. Labopin, A. Nagler, 2019, Bone Marrow Transplantation.

Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT

N. Kröger, C. Crawley, N. Russell, 2021, Bone Marrow Transplantation.

Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects

N. Kröger, D. Niederwieser, J. Beyersmann, 2018, Haematologica.

T‐cell–depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT)

L. Kanz, M. Labopin, A. Nagler, 2018, Cancer.

Eculizumab Therapy of Adult TA-TMA: A High Response Rate Is Associated with a High Infection-Related Mortality

L. Bullinger, H. Döhner, F. Kuchenbauer, 2016 .

Outcomes of Unrelated Cord Blood and Haploidentical Stem Cell Transplantation in Adults with Acute Leukaemia.

P. Bartolomeo, M. Labopin, M. Martelli, 2005 .

Allogeneic Hematopoietic Cell Transplantation Can Cure Some Patients with Acute Leukemia in Relapse or Primary Induction Failure: A CIBMTR Study.

J. Klein, J. Dipersio, M. Tallman, 2009 .

Reduced‐intensity conditioning followed by T‐cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse

K. Döhner, H. Döhner, S. Stilgenbauer, 2007, British journal of haematology.

Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation.

H. Heimpel, H. Schrezenmeier, B. Hertenstein, 1993, Bone marrow transplantation.

transplantation: a retrospective collaborative analysis High-resolution HLA matching in hematopoietic stem cell

K. Schwarz, H. Einsele, M. Pfreundschuh, 2013 .

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

N. Schmitz, H. Döhner, M. Hallek, 2010 .

Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT

J. Esteve, A. Ganser, M. Labopin, 2015 .

Physicians' prognostic estimates of survival for patients undergoing allogeneic hematopoietic stem cell transplantation.

W. Larbig, H. Kächele, D. Bunjes, 2008, Journal of psychosomatic research.

Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies.

T. Lipp, E. Thiel, N. Kröger, 2009 .

Molecular imaging of proliferation in malignant lymphoma.

T. Mattfeldt, F. Mottaghy, H. Döhner, 2006, Cancer research.

Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.

J. Dipersio, M. Tallman, Tao Wang, 2009 .

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study

I. Yakoub-Agha, E. Deconinck, M. Itälä-Remes, 2023, European journal of haematology.

Successful adoptive immunotherapy for relapse of AML 9 years after T‐cell‐depleted BMT

J. Finke, D. Bunjes, H. Bertz, 1998, British journal of haematology.

Monitoring of strength, inflammation and muscle function in allogenic stem-cell transplantation patients – a pilot study for novel biomarker and risk stratification determination

J. Kirsten, D. Bizjak, D. Bunjes, 2023, Frontiers in Immunology.

Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation

H. Döhner, F. Kuchenbauer, H. Schrezenmeier, 2020, Leukemia & lymphoma.

Treatment results of nine patients with burkitt's lymphoma

H. Heimpel, D. Bunjes, B. Anger, 1986, Blut.

Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study

M. Labopin, P. Chevallier, A. Nagler, 2023, Blood Advances.

Reversal of Acquired von Willebrand Disease after Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with High Risk Chronic Lymphocytic Leukemia.

H. Döhner, M. Griesshammer, C. Langer, 2004 .

Polyoma virus-associated interstitial nephritis in a patient with acute myeloic leukaemia and peripheral blood stem cell transplantation.

F. Keller, S. Stracke, U. Helmchen, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

N. Kröger, M. Labopin, D. Blaise, 2009 .

Sarcopenia Screening Allows Identifying High-Risk Patients for Allogenic Stem Cell Transplantation

J. Steinacker, J. Kirsten, G. Treff, 2021, Cancers.

Optimization of Radiolabeling of a [90Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation

H. Döhner, G. Glatting, V. Prasad, 2023, Cancers.

Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody Radioimmunotherapy.

G. Glatting, A. Beer, P. Kletting, 2015, Cancer biotherapy & radiopharmaceuticals.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

N. Schmitz, H. Döhner, M. Hallek, 2016 .